Professor Erlie Jiang is internationally recognized for pioneering hematopoietic stem cell transplantation research, directing a center performing 800+ transplants annually with outcomes matching global standards. His team integrates clinical cohort studies, AI modeling, multi-omics analysis, and translational research to address transplantation complications including GVHD, fungal infections, and disease prognosis. Their groundbreaking investigations span the entire transplantation process—from stem cell biology (heterogeneity and damage mechanisms) to immune regulation (T-cell function and stability), and from clinical outcomes (genetic predictors of prognosis) to complication management (GVHD prevention and microbiological factors). These comprehensive contributions have generated 400+ publications in premier journals including Blood, Science Immunology, Nature Communications, Cellular & Molecular Immunology, American Journal of Hematology, Leukemia and Experimental Hematology & Oncology.
MD, Internal Medicine, Peking Union Medical College, Beijing, China, 2000-2005
BM, Clinical Medicine, Bethune Medical University, Jilin, China, 1989-1995
Chief Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2017-
Associate Chief Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2008-2017
Postdoctoral Fellow, Baylor College of Medicine, 2010-2012
Attending Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2005-2008
Resident Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1995-2000
PRINCIPAL HONORS, AWARDS:
2023 First Prize, Tianjin Anti-Cancer Association Science and Technology Award (Lead Investigator, Project No. 2023TJK-1-01-d01)
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
2025-Present Chair, Expert Committee on Leukemia, Chinese Society of Clinical Oncology (CSCO)
2023-Present Chair, Hematopoietic Stem Cell Transplantation Specialized Committee, China Primary Health Care Foundation
2021-Present Chair, Leukemia Autologous Transplantation Collaborative Group, China Alliance for Blood Diseases
2021-2024 Vice Chair, China Autologous Hematopoietic Stem Cell Transplantation Working Group, Chinese Society of Clinical Oncology (CSCO)
2023-Present Vice Chair, Hematopoietic Stem Cell Transplantation and Cell Therapy Professional Committee, China Medical Education Association
2021-Present Vice Chair, Application Section of Hematopoietic Stem Cell, Hematology Branch of Chinese Medical Association
2019-Present Vice Chair, Hematopoietic Stem Cell Transplantation and Cellular Therapy Group, Hematologic Oncology Committee, China Anti-Cancer Association
2019-Present Vice Chair, Hematopoietic Stem Cell Transplantation and Cellular Therapy Group, Hematologic Oncology Committee, China Anti-Cancer Association
2022-Present Standing Director, Surgery and Related Controlled Spaces Branch, National Health Industry Enterprise Management Association
2018-Present Standing Committee Member, Hematologic Oncology Committee, China Anti-Cancer Association
2021-Present Member, Cell Research and Therapy Professional Committee, Chinese Research Hospital Association
2020-2022 Expert, Talent Evaluation Project, Talent Exchange Service Center, National Health Commission
2019-Present Member, Second Committee of China MDS and Myeloproliferative Tumor Working Group, Hematologic Oncology Professional Committee, China Anti-Cancer Association
2019-Present Vice Chair, Pan-Jin Expert Collaboration Group, Hemophagocytic Syndrome China Expert Alliance
2022-Present Vice Chair, Respiratory and Critical Care Medicine Professional Committee, Tianjin Pharmacological Society
2021-Present Vice President, Tianjin Society of Hematology and Regenerative Medicine
2021-Present Member, Hematology Branch, China International Exchange and Promotive Association for Medicine & Health
2021-Present Standing Member, Transplantation and Health Professional Committee, Tianjin Medical and Health Association
2022-Present Standing Member, Geriatric Oncology Professional Committee, Tianjin Anti-Cancer Association
2022-Present Standing Member, Stem Cell and Translational Medicine Professional Committee, Tianjin Society of Integrative Medicine
2020-2023 Member, Hematology Professional Committee, Tianjin Society of Integrative Medicine
2023-Present Standing Member, Stem Cell Engineering Technology Branch, Chinese Society of Biomedical Engineering
2019-2022 Member, Clinical Nutrition Therapy Professional Committee, Tianjin Society of Integrative Medicine
2023-Present Standing Member, Hematology Professional Committee, Tianjin Medical and Health Association
2021-Present Editorial Board Member, Chinese General Practice Fourth Editorial Board
2023-Present Editorial Board Member, Blood and Genomics
2022-Present Editorial Board Member, Chinese Journal of Blood Transfusion, Institute of Blood Transfusion, Chinese Academy of Medical Sciences
2020-Present Editorial Board Member, Chinese Journal of Hematology
2014-2018 Editorial Board Member, Chinese Journal of Infection Control
SELECTED PUBLICATIONS:
1. Xue R*, Dai M*, Jiang E*, Ou X*, Huang F, Fan Z, Xu N, Yan C, Nie D, Liang X, Chen H, Ye J, Jiang L, Liu H, Jin H, Lin R, Zhang Y, Sun J, Han M, Liu Q, Wang Y, Xuan L. Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT. Blood Cancer J. 2025 Feb 19;15(1):21.
2. Cao, J., Zheng, Y., Li, R., Feng, D., Ni, X., Gao, H., Wang, M., Cao, Y., Zhai, W., Zhang, R., Yang, D., He, Y., Feng, S., Han, M., Zhang, H*., Pang, A*. and Jiang, E*. 2025, CSF3R Mutations in Hematological Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol, 100: 925-927.
3. Feng Y, Qi S, Hu Y, Yan W, Ji Y, Wang M, Gong X, Shen Q, Zhang W, Liu H, Zhang X, Chen M, Chen E, Zhai X, He Y, Yang D, Pang A, Han M, Gale RP, Sun Z, Jiang E*, Chen J. New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery. Leukemia. 2024 Dec;38(12):2735-2738.
4. Luo J, Zhou Y, Wang M, Zhang J, Jiang E*. Inflammasomes: potential therapeutic targets in hematopoietic stem cell transplantation. Cell Commun Signal. 2024 Dec 18;22(1):596.
5. Jiang E, Qian K, Wang L, Yang D, Shao Y, Hu L, Li Y, Yao C, Han M, Hou X, Liu D. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial. BMC Med. 2024 Nov 25;22(1):555.
6. Gao H, Zhang Z, Wang J, Jia Y, Zheng Y, Pei X, Zhai W, Zhang R, Chen X, Ma Q, Wei J, Yang D, Pang A, He Y, Feng S, Zhang H, Du X, Song X, Liu Y*, Zou D*, Jiang E*. Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China. Exp Hematol Oncol. 2024 Aug 24;13(1):88.
7. Niu, Q., Zhang, H., Wang, F., Xu, X., Luo, Y., He, B., Shi, M., Jiang, E*., & Feng, X*. (2024). GSNOR overexpression enhances CAR-T cell stemness and anti-tumor function by enforcing mitochondrial fitness. Mol Ther, 2024 June;32(6), 1875–1894.
8. Cao J, Pan P, Feng D …Jiang E*, Aiming Feng. Posaconazole gastro-resistant tablets for preventing invasive fungal disease after haematopoietic stem cell transplantation: a propensity-matched cohort study. Clin Microbiol Infect. 2024;30(12):1585-1591.
9. Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W, Chen X, Ma Q, Yang D, Wei J, Pang A, He Y, Feng S, Wang J, Han M, Jiang E*. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol. 2024 Feb 15;13(1):16.
10. Wang F, Li Y, Yang Z, Cao W, Liu Y, Zhao L, Zhang T, Zhao C, Yu J, Yu J, Zhou J, Zhang X, Li PP, Han M, Feng S, Ng BW, Hu ZW, Jiang E*, Li K*, Cui B*. Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Nat Commun. 2024 Jan 3;15(1):203.
11. Huo Y, Wu L, Pang A, Li Q, Hong F, Zhu C, Yang Z, Dai W, Zheng Y, Meng Q, Sun J, Ma S, Hu L, Zhu P, Dong F, Gao X, Jiang E*, Hao S*, Cheng T*. Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation. Sci Immunol. 2023 Mar 17;8(81):eabn6429.
12. Cao Y, Gong X, Feng Y, Wang M, Song Z, Guo Y*, Sun Z*, Jiang E*, Chen J*. The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023 Feb;98(2):309-321.
13. Hu, L., Yin, X., Zhang, Y., Pang, A., Xie, X., Yang, S., Zhu, C., Li, Y., Zhang, B., Huang, Y., Tian, Y., Wang, M., Cao, W., Chen, S., Zheng, Y., Ma, S., Dong, F., Hao, S., Feng, S., Ru, Y., … Jiang E*, Cheng T*. Radiation-induced bystander effects impair transplanted human hematopoietic stem cells via oxidative DNA damage. Blood, 2021，137(24), 3339–3350.
14. Luo Y, Xu C, Wang B, …Jiang E*, Shi L*, Feng X*, et al. Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human Treg compartment. Nat Commun. 2021;12(1):3913.
15. X Su, Q Wang, W Guo, X Pei, Q Niu, M Liu, Y Liu, S Chen, S Feng, Y He, D Yang, R Zhang, Q Ma, W Zhai, A Pang, J Wei, Y Huang, Y Luo, M Han*, X Feng* and E Jiang*. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation. Cell Mol Immunol 2020;17:483-495.